½ÃÀ庸°í¼­
»óǰÄÚµå
1404794

¼öµÎÁõ ¼ÇÆ® ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Hydrocephalus Shunts Market Size, Share & Trends Analysis Report By Product (Valves, Catheter), By End-use (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 110 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼öµÎÁõ ¼ÇÆ® ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 3.99%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÇ¾î 2030³â±îÁö 5¾ï 9,942¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Å°æÁúȯ Ä¡·á¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ ÀÚ±ÝÀÇ °³¹ß, Á¦Ç° °³¹ßÀ» À§ÇÑ ÀÓ»ó ¿¬±¸ Áõ°¡, Á¦Ç° Ãâ½Ã¸¦ À§ÇÑ ±ÔÁ¦ ½ÂÀÎ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

¾÷°èÀÇ ÁÖ¿ä ¾÷üµéÀº ¼öµÎÁõ ¹× ±âŸ ½Å°æ ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ÀåÄ¡ °³¹ß¿¡µµ Âü¿©Çϰí ÀÖ½À´Ï´Ù. Á¦Ç° Æ÷Æ®Æú¸®¿À °³¹ßÀ» À§ÇÑ ÀÓ»ó ¿¬±¸ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù, CereVasc, Inc.´Â Àü¿°¼º ¼öµÎÁõ Ä¡·á¿¡ ´ëÇÑ ÀåÄ¡ÀÇ È¿°ú¸¦ Æò°¡Çϱâ À§ÇØ ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇèÀÇ ÀÏȯÀ¸·Î 30¹øÂ° ȯÀÚ°¡ eShunt Implant¸¦ ¹Þ¾Ò´Ù°í ¹àÇû½À´Ï´Ù. ÀÌ ÆÄÀÏ·µ ½ÃÇè Áß Ã¹ ¹øÂ° ½ÃÇèÀº ¾Æ¸£ÇîÆ¼³ª ÀǾàǰ, ½Äǰ ¹× ÀÇ·á±â±â °ü¸®±¹(ANMAT)ÀÇ ±ÔÁ¦ ½ÂÀÎÀ» ¹Þ¾Æ ¾Æ¸£ÇîÆ¼³ª¿¡¼­ ÁøÇàµÇ¾ú°í, µÎ ¹øÂ° ½ÃÇèÀº ¹Ì±¹ FDAÀÇ ÀÓ»ó½ÃÇè¿ë ÀÇ·á±â±â Àû¿ë Á¦¿Ü(IDE) ½ÂÀÎÀ» ¹Þ¾Æ ¹Ì±¹¿¡¼­ ÁøÇàµÇ¾úÀ¸¸ç, Àü¿°¼º ¼öµÎÁõ¿¡ ´ëÇÑ ÃÖ¼Òħ½ÀÀû Ä¡·á¹ýÀ» ¿¬±¸Çß½À´Ï´Ù. ÀÌó·³ ÀÓ»ó½ÃÇè¿¡¼­ ¾òÀº ÁÁÀº °á°ú°¡ ÇâÈÄ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼öµÎÁõ ¼ÇÆ® ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â ¹ëºê ºÎ¹®ÀÌ 2023³â 71.26%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. Á¶Á¤ °¡´ÉÇÑ ¹ëºê¸¦ »ç¿ëÇϸé ÀÇ·á Àü¹®°¡°¡ ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸¿¡ µû¶ó ¼³Á¤À» »ç¿ëÀÚ Á¤ÀÇÇÏ¿© Ä¡·á °úÁ¤À» ÃÖÀûÈ­ ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • º´¿ø ºÎ¹®Àº 2023³â Àüü ÃÖÁ¾ »ç¿ëÀÚ ½ÃÀåÀÇ 75.87%¸¦ Â÷ÁöÇß½À´Ï´Ù. ¼ö¼ú, Ä¡·á ¹× Ä¡·á¸¦ À§ÇØ ÀÔ¿øÇϴ ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó °¡±î¿î ¹Ì·¡¿¡ ¼öµÎÁõ ¼ÇÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì´Â ½Å°æÁúȯ°ú ¼öµÎÁõ ¹ßº´·üÀÌ ³ô¾Æ 2023³â Áö¿ªº° Àüü ½ÃÀå ¸ÅÃâ ºñÁßÀÌ 37.97%·Î °¡Àå ³ôÀº °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.
  • ¼öµÎÁõ ¼ÇÆ® ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Medtronic, Aesculap, Spiegelberg GmbH &Co. Surgiwear Ltd, Bicakcilar.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼öµÎÁõ ¼ÇÆ® ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • º¸±Þ ¹× ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
    • »óȯ ÇÁ·¹ÀÓ¿öÅ©
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¼öµÎÁõ ¼ÇÆ® ½ÃÀå ºÐ¼® Åø
    • ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • ÁÖ¿ä °Å·¡¿Í Àü·«Àû Á¦ÈÞ ºÐ¼®
    • ½ÃÀå ÁøÃâ Àü·«

Á¦4Àå ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
    • ¹ëºê
    • Ä«Å×ÅÍ
  • Á¦Ç° ½ÃÀå Á¡À¯À², 2023³â & 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • Á¦Ç°º° ¼öµÎÁõ ¼ÇÆ® ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • ¹ëºê
    • Ä«Å×ÅÍ

Á¦5Àå ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

  • Á¤ÀÇ¿Í ¹üÀ§
    • º´¿ø
    • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
  • ºÎ¹® ´ë½Ãº¸µå
  • ÃÖÁ¾ ¿ëµµº° ¼öµÎÁõ ¼ÇÆ® ½ÃÀå Àü¸Á
  • ÀÌÇÏ ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
    • º´¿ø
    • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)

Á¦6Àå ¼öµÎÁõ ¼ÇÆ® ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
  • Áö¿ª ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°èÀÇ Áö¿ª ½ÃÀå ½º³À¼ô
  • Áö¿ª ½ÃÀå Á¡À¯À²°ú ÁÖ¿ä ±â¾÷, 2023³â
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¿¬·ÉÃþ, 2018-2030³â ¿¹Ãø°ú µ¿Ç⠺м®
  • ºÏ¹Ì
    • ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Àεµ
    • Áß±¹
    • Çѱ¹
    • È£ÁÖ
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ȸ»ç/°æÀï»ç ºÐ·ù
    • Çõ½Å±â¾÷
  • º¥´õ ±¸µµ
    • Sophysa
    • CHRISTOPH MIETHKE GMBH &CO. KG
    • Hpbio
    • G. Surgiwear Ltd
    • Bicakcilar
LSH 24.01.23

Hydrocephalus Shunts Market Growth & Trends:

The global hydrocephalus shunts market size is anticipated to reach USD 599.42 million by 2030, registering at a CAGR of 3.99% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing public and private funding for neurological disorders treatments, increasing clinical studies for the product development, and the rise in regulatory approval for product launch are key contributors to the market growth.

The industry key players are also involved in developing devices for the treatment of hydrocephalus and other neurological disorders. The increasing clinical studies for the product portfolio development further drives the growth of the market. For instance, in October 2023, as part of the ongoing clinical trials evaluating the effectiveness of the device for the treatment of communicating hydrocephalus, CereVasc, Inc. revealed that a milestone 30th patient received the eShunt Implant. The first of these pilot studies, which was carried out in Argentina under regulatory approval from the National Administration of Drugs, Food and Medical Devices (ANMAT), and the second was executed in the U.S. under FDA approval for an Investigational Device Exemption (IDE) to study a minimally invasive treatment for communicating hydrocephalus. Thus, due to such positive outcomes from the clinical studies will drive the market growth in near future.

Hydrocephalus Shunts Market Report Highlights:

  • Based on product, valves segment dominated the market in 2023 with a share of 71.26%. Adjustable valves empower healthcare professionals to customize settings according to the patient's specific needs, thereby optimizing the treatment process.
  • The hospitals segment held 75.87% of the overall end user market in 2023. Increasing number of patients being admitted to hospitals due to surgeries, therapies, and treatments is expected to increase the demand for hydrocephalus shunts in near future.
  • North America dominated the overall regional market with the highest revenue share of 37.97% in 2023 owing to high incidence rate of neurological disease & hydrocephalus in this region.
  • Key players in hydrocephalus shunts market include Medtronic, Aesculap, Inc., Spiegelberg GmbH & Co. KG., Integra LifeSciences, Sophysa, CHRISTOPH MIETHKE GMBH & CO. KG, Hpbio, G. Surgiwear Ltd, and Bicakcilar.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. End-use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Age group outlook
    • 2.2.3. End-use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hydrocephalus Shunts Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market driver analysis
      • 3.4.1.1. Increase in number of patients suffering from hydrocephalus
      • 3.4.1.2. Advancements in shunt technology
      • 3.4.1.3. Growing healthcare awareness
    • 3.4.2. Market restraint analysis
      • 3.4.2.1. Complex regulatory framework
  • 3.5. Hydrocephalus Shunts Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape
    • 3.5.3. Major Deals & Strategic Alliances Analysis
    • 3.5.4. Market Entry Strategies

Chapter 4. Hydrocephalus Shunts Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Valves
    • 4.1.2. Catheter
  • 4.2. Product Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Hydrocephalus Shunts Market by Product Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Valves
      • 4.5.1.1. Valves market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Catheter
      • 4.5.2.1. Catheter market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Hydrocephalus Shunts Market: End Use Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Hospitals
    • 5.1.2. Ambulatory Surgical Centers
  • 5.2. End Use Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Hydrocephalus Shunts Market by End-Use Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Hospitals
      • 5.5.1.1. Hospitals market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2. Ambulatory Surgical Centers
      • 5.5.2.1. Ambulatory surgical centers market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Hydrocephalus Shunts Market: Regional Estimates & Trend Analysis

  • 6.1. Regional market share analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Regional Market Share and Leading Players, 2023
    • 6.4.1. North America
    • 6.4.2. Europe
    • 6.4.3. Asia Pacific
    • 6.4.4. Latin America
    • 6.4.5. Middle East and Africa
  • 6.5. Market Age Group, & Forecasts and Trend Analysis, 2018 to 2030
  • 6.6. North America
    • 6.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. U.S.
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Reimbursement scenario
      • 6.6.2.5. U.S. market estimates and forecasts, 2018 - 2030
    • 6.6.3. Canada
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Reimbursement scenario
      • 6.6.3.5. Canada market estimates and forecasts, 2018 - 2030
  • 6.7. Europe
    • 6.7.1. UK
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Competitive scenario
      • 6.7.1.3. Regulatory framework
      • 6.7.1.4. Reimbursement scenario
      • 6.7.1.5. UK market estimates and forecasts, 2018 - 2030
    • 6.7.2. Germany
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. Reimbursement scenario
      • 6.7.2.5. Germany market estimates and forecasts, 2018 - 2030
    • 6.7.3. France
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Reimbursement scenario
      • 6.7.3.5. France market estimates and forecasts, 2018 - 2030
    • 6.7.4. Italy
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. Reimbursement scenario
      • 6.7.4.5. Italy market estimates and forecasts, 2018 - 2030
    • 6.7.5. Spain
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Reimbursement scenario
      • 6.7.5.5. Spain market estimates and forecasts, 2018 - 2030
    • 6.7.6. Denmark
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Competitive scenario
      • 6.7.6.3. Regulatory framework
      • 6.7.6.4. Reimbursement scenario
      • 6.7.6.5. Denmark market estimates and forecasts, 2018 - 2030
    • 6.7.7. Sweden
      • 6.7.7.1. Key country dynamics
      • 6.7.7.2. Competitive scenario
      • 6.7.7.3. Regulatory framework
      • 6.7.7.4. Reimbursement scenario
      • 6.7.7.5. Sweden market estimates and forecasts, 2018 - 2030
    • 6.7.8. Norway
      • 6.7.8.1. Key country dynamics
      • 6.7.8.2. Competitive scenario
      • 6.7.8.3. Regulatory framework
      • 6.7.8.4. Reimbursement scenario
      • 6.7.8.5. Norway market estimates and forecasts, 2018 - 2030
  • 6.8. Asia Pacific
    • 6.8.1. Japan
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Competitive scenario
      • 6.8.1.3. Regulatory framework
      • 6.8.1.4. Reimbursement scenario
      • 6.8.1.5. Japan market estimates and forecasts, 2018 - 2030
    • 6.8.2. India
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Competitive scenario
      • 6.8.2.3. Regulatory framework
      • 6.8.2.4. Reimbursement scenario
      • 6.8.2.5. India market estimates and forecasts, 2018 - 2030
    • 6.8.3. China
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Competitive scenario
      • 6.8.3.3. Regulatory framework
      • 6.8.3.4. Reimbursement scenario
      • 6.8.3.5. China market estimates and forecasts, 2018 - 2030
    • 6.8.4. South Korea
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Competitive scenario
      • 6.8.4.3. Regulatory framework
      • 6.8.4.4. Reimbursement scenario
      • 6.8.4.5. South Korea market estimates and forecasts, 2018 - 2030
    • 6.8.5. Australia
      • 6.8.5.1. Key country dynamics
      • 6.8.5.2. Competitive scenario
      • 6.8.5.3. Regulatory framework
      • 6.8.5.4. Reimbursement scenario
      • 6.8.5.5. Australia market estimates and forecasts, 2018 - 2030
    • 6.8.6. Thailand
      • 6.8.6.1. Key country dynamics
      • 6.8.6.2. Competitive scenario
      • 6.8.6.3. Regulatory framework
      • 6.8.6.4. Reimbursement scenario
      • 6.8.6.5. Thailand market estimates and forecasts, 2018 - 2030
  • 6.9. Latin America
    • 6.9.1. Brazil
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Competitive scenario
      • 6.9.1.3. Regulatory framework
      • 6.9.1.4. Reimbursement scenario
      • 6.9.1.5. Brazil market estimates and forecasts, 2018 - 2030
    • 6.9.2. Mexico
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Competitive scenario
      • 6.9.2.3. Regulatory framework
      • 6.9.2.4. Reimbursement scenario
      • 6.9.2.5. Mexico market estimates and forecasts, 2018 - 2030
    • 6.9.3. Argentina
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Competitive scenario
      • 6.9.3.3. Regulatory framework
      • 6.9.3.4. Reimbursement scenario
      • 6.9.3.5. Argentina market estimates and forecasts, 2018 - 2030
  • 6.10. MEA
    • 6.10.1. South Africa
      • 6.10.1.1. Key country dynamics
      • 6.10.1.2. Competitive scenario
      • 6.10.1.3. Regulatory framework
      • 6.10.1.4. Reimbursement scenario
      • 6.10.1.5. South Africa market estimates and forecasts, 2018 - 2030
    • 6.10.2. Saudi Arabia
      • 6.10.2.1. Key country dynamics
      • 6.10.2.2. Competitive scenario
      • 6.10.2.3. Regulatory framework
      • 6.10.2.4. Reimbursement scenario
      • 6.10.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
    • 6.10.3. UAE
      • 6.10.3.1. Key country dynamics
      • 6.10.3.2. Competitive scenario
      • 6.10.3.3. Regulatory framework
      • 6.10.3.4. Reimbursement scenario
      • 6.10.3.5. UAE market estimates and forecasts, 2018 - 2030
    • 6.10.4. Kuwait
      • 6.10.4.1. Key country dynamics
      • 6.10.4.2. Competitive scenario
      • 6.10.4.3. Regulatory framework
      • 6.10.4.4. Reimbursement scenario
      • 6.10.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Innovators
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. Medtronic
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Aesculap, Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Spiegelberg GmbH & Co. KG.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Integra LifeSciences
      • 7.3.7.1. Company overview
      • . Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Sophysa
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. CHRISTOPH MIETHKE GMBH & CO. KG
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Hpbio
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. G. Surgiwear Ltd
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Bicakcilar
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦